ArticleProceedings of the National Academy of Sciences of the United States of America2021
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Development of a Cell-Based Recombinant Green Fluorescent Protein Assay System for Generalized Discovery of Viral Protease Inhibitors.ACS pharmacology & translational science · 2025Article
- An Interpretable Deep Learning and Molecular Docking Framework for Repurposing Existing Drugs as Inhibitors of SARS-CoV-2 Main Protease.Molecules (Basel, Switzerland) · 2025Article
- Identification of potential SARS-CoV-2 inhibitors among well-tolerated drugs using drug repurposing and in vitro approaches.Scientific reports · 2025Article
- Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach.Acta pharmaceutica Sinica. B · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.European journal of medicinal chemistry · 2023Review
- Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.International journal of molecular sciences · 2023Article
- Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19.Thrombosis update · 2023Review
- SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.Accounts of chemical research · 2023Article
- PredictingACS omega · 2022Article
- Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.Annals of medicine · 2022Review
- Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry · 2022Review
- Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor.ACS infectious diseases · 2022Article
- Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays.Acta pharmaceutica Sinica. B · 2022Article
- Editorial of Special Column on Antiviral Drug Discovery and Pharmacology.Acta pharmaceutica Sinica. B · 2022Article
- Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor.Research square · 2022Article
- Article
- Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.ACS central science · 2022Article
- Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors.ACS pharmacology & translational science · 2022Article
- Peptidic Sulfhydryl for Interfacing Nanocrystals and Subsequent Sensing of SARS-CoV-2 Protease.Chemistry of materials : a publication of the American Chemical Society · 2022Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.